Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Local administration of immunomodulators.

C M Pinsky

    Seminars in Oncology
    |June 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Local biologic response modifier (BRM) administration shows frequent clinical responses in specific patient populations. Further research into effector cells, cytokines, and animal models can elucidate BRM therapy

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer.

    Annals of surgery·1997
    Same author

    Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1996
    Same author

    Rapid imaging of infections with a monoclonal antibody fragment (LeukoScan).

    Clinical orthopaedics and related research·1996
    Same author

    Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment.

    Cancer research·1995
    Same author

    Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.

    Cancer research·1992
    Same author

    Lymphoma imaging with a new technetium-99m labelled antibody, LL2.

    European journal of nuclear medicine·1992

    Area of Science:

    • Immunology
    • Oncology
    • Pharmacology

    Background:

    • Biologic response modifiers (BRMs) are used in cancer therapy.
    • Local administration of BRMs has potential therapeutic applications.
    • Understanding BRM mechanisms is crucial for optimizing cancer treatment.

    Purpose of the Study:

    • To summarize outcomes of local BRM administration.
    • To investigate the mechanisms of action for effective BRM therapy.
    • To compare clinical trial results with animal model findings.

    Main Methods:

    • Review of clinical data on local BRM administration.
    • Analysis of effector cells and cytokines in responding patients.
    • Comparative analysis of clinical and experimental animal study results.

    Related Experiment Videos

    Main Results:

    • Local BRM administration is applicable in limited clinical settings.
    • Frequent clinical responses are observed in appropriate patient populations.
    • Effector cells and cytokines provide insights into BRM mechanisms.

    Conclusions:

    • Local BRM therapy can be effective in selected patients.
    • Further research is needed to fully understand BRM mechanisms.
    • Comparative studies enhance the elucidation of BRM's antitumor effects.